Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ulta Beauty

Walmart

QuidelOrtho Corp

Walmart, Abbott Labs, Ulta Beauty and Quidel were our top stock trades for Friday. So, here's what the charts are trying to tell us now.

4 Top Stock Trades for Friday: WMT, ULTA, ABT, QDEL

Abott’s pocket-sized, $5, 15-minute COVID-19 test was just granted emergency use authorization.
Abbott Laboratories has just been granted emergency use authorization by the Food and Drug Administration for its pocket-sized, $5, 15-minute COVID-19 antigen test.

Abbott’s rapid COVID-19 test: Here’s how it’s different from the rest

The Trump administration has struck a $750 million deal with Abbott Laboratories ABT, +8.26% to buy 150 million of the company's new rapid-response COVID-19 antigen tests.

Trump administration makes $750 million deal to buy 150 million of Abbott's new coronavirus tests

A recently authorized point-of-care COVID-19 test could be the most popular one yet.

Abbott to Receive Order for 150 Million Rapid COVID-19 Tests

Microsoft

A fast and cheap test could hasten the economic recovery, and Microsoft is now working with Walmart to acquire the popular social media app.

Dow Jones Jumps on Rapid COVID-19 Test; Microsoft and Walmart Team Up for TikTok Bid

President Donald Trump plans to announce Thursday the purchase of 150 million rapid Covid-19 tests as part of a $750 million agreement with Abbott Laboratories, a White House official confirmed to NBC News.

Trump to announce $750 million deal with Abbott for at least 150 million rapid coronavirus tests

Hope for an end to coronavirus worries is continuing the bull market run.

Fed Lifts Stock Markets; Abbott's $5 Quick Test Gives Travel Stocks Big Gains

Abbott Labs got emergency approval from the US Food and Drug Administration for its rapid antigen test, which can detect a Covid-19 infection in 15 minutes.

This $5 rapid test is a potential game-changer in Covid testing

Abbott Laboratories said on Wednesday it won U.S. marketing authorization for a Covid-19 portable antigen test that can deliver results within 15 minutes and will sell for $5.

Op-Ed: Abbott CEO says coronavirus testing needs to be done on a massive scale to fight pandemic

Abbott Laboratories' winning Food and Drug Administration emergency use authorization for an easy-to-perform, 15-minute, $5 coronavirus test sent ABT stock soaring in Thursday trading. 
The post Abbott Labs Stock Jumps After FDA Approves Its 15-Minute, $5 Coronavirus Test appeared first on Investor's Business Daily.

Abbott Labs Stock Jumps After FDA Approves Its 15-Minute, $5 Coronavirus Test

Abbott Labs' got emergency approval from the US Food and Drug Administration for its rapid antigen test, which can detect a Covid-19 infection in 15 minutes.

A $5 Covid-19 test from Abbott Labs just got emergency FDA authorization

Shares of Abbott Laboratories ABT, +0.70% gained 9.1% in premarket trading on Thursday, the day after the company had announced regulatory authorization for a new COVID-19 test that costs $5, does not require instrumentation, and can produce a result in 15 minutes.

Abbott's stock jumps 9% following authorization of its rapid $5 COVID-19 test

The United States Food and Drug Administration granted emergency use authorization to a 15-minute COVID-19 test produced by Abbott Laboratories (NYSE: ABT) on Wednesday.

Abbott Gets FDA Emergency Use Approval For $5 Rapid COVID-19 Test

The cheap, rapid test could help get people back to work.

Abbott Receives FDA Authorization for a $5 App-Enabled 15-Minute COVID-19 Test

The rapid antigen test produces results in 15 minutes.

$5 Rapid Covid-19 Test From Abbott Labs Gets Emergency FDA Approval

Abbott wins U.S. authorization for $5 rapid Covid-19 antigen

ABBOTT PARK, Ill., Aug. 26, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S.

Abbott's Fast, $5, 15-Minute, Easy-to-Use COVID-19 Antigen Test Receives FDA Emergency Use Authorization; Mobile App Displays Test Results to Help Our Return to Daily Life; Ramping Production to 50 Million Tests a Month

PepsiCo

Ross Stores

V.F.

Dividend aristocrats have increased dividends for at least 25 consecutive years. Here are four of the best dividend aristocrats you can buy.

The 4 Best Dividend Aristocrats to Buy Now

Lowe's

Becton, Dickinson and Co.

Home Depot

S&P Global

If you're looking to protect your income, dividend stocks are the way to go. Our deep learning algorithms and Artificial Intelligence ("AI") technology has gone through some data to provide you with the Top Dividend Stocks to invest in with your portfolio.

Top Dividend Stocks For August

Don't hesitate to buy ABT stock as vast quantities of Covid-19 test shipments indicate robust business for Abbott Laboratories.
The post Abbott Laboratories Is a Surefire Covid-19 Diagnostics Investment appeared first on InvestorPlace.

Abbott Laboratories Is a Surefire Covid-19 Diagnostics Investment

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Why Is Abbott (ABT) Up 3.7% Since Last Earnings Report?

Gilead Sciences

Eli Lilly

No one wants COVID-19 vaccines to fail. But if you want to hedge for the possibility, check out these solid stocks.

3 Large-Cap Stocks That Should Soar If Coronavirus Vaccines Flop

Thermo Fisher Scientific

Spending on leisure and vice has remained high in recent months, making this sector one to watch during this period of uncertainty.

3 Charts That Suggest Sin Stocks Are Headed Higher

Coca-Cola

These are investments you can buy and forget about.

3 Safe Stocks to Hold Through the Next Market Crash

Abbott’s stock (NYSE: ABT) lost more than 27% – dropping from $87 at the beginning of the year to below $63 in late March – then spiked 58% to around $100 now. That means it is well above the levels where it started the year.

News for Abbott Labs Stock (ABT)